<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27608771</PMID><DateCompleted><Year>2018</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><PubDate><Year>2016</Year><Month>Sep</Month><Day>09</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Amphotericin B Inhibits Enterovirus 71 Replication by Impeding Viral Entry.</ArticleTitle><Pagination><StartPage>33150</StartPage><MedlinePgn>33150</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">33150</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/srep33150</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) infection causes hand-foot-and-mouth disease that leads to cardiopulmonary complications and death in young children. There is thus an urgent need to find new treatments to control EV71 infection. In this study, we report potent inhibition of EV71 by a polyene antibiotic Amphotericin B. Amphotericin B profoundly diminished the expression of EV71 RNA and viral proteins in the RD cells and the HEK293 cells. As a result, EV71 production was inhibited by Amphotericin B with an EC50 (50% effective concentration) of 1.75&#x2009;&#x3bc;M in RD cells and 0.32&#x2009;&#x3bc;M in 293 cells. In addition to EV71, EV68 was also strongly inhibited by Amphotericin B. Results of mechanistic studies revealed that Amphotericin B targeted the early stage of EV71 infection through impairing the attachment and internalization of EV71 by host cells. As an effective anti-fungi drug, Amphotericin B thus holds the promise of formulating a novel therapeutic to treat EV71 infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Fengwen</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>MOH Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, and Center for AIDS Research, Chinese Academy of Medical Sciences &amp;Peking Union Medical College, Beijing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Xiaoxiao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>MOH Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, and Center for AIDS Research, Chinese Academy of Medical Sciences &amp;Peking Union Medical College, Beijing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Siqi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>MOH Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, and Center for AIDS Research, Chinese Academy of Medical Sciences &amp;Peking Union Medical College, Beijing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>MOH Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, and Center for AIDS Research, Chinese Academy of Medical Sciences &amp;Peking Union Medical College, Beijing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Lijuan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>MOH Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, and Center for AIDS Research, Chinese Academy of Medical Sciences &amp;Peking Union Medical College, Beijing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mei</LastName><ForeName>Shan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>MOH Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, and Center for AIDS Research, Chinese Academy of Medical Sciences &amp;Peking Union Medical College, Beijing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Tingting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>MOH Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, and Center for AIDS Research, Chinese Academy of Medical Sciences &amp;Peking Union Medical College, Beijing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>MOH Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, and Center for AIDS Research, Chinese Academy of Medical Sciences &amp;Peking Union Medical College, Beijing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Lili</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>MOH Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, and Center for AIDS Research, Chinese Academy of Medical Sciences &amp;Peking Union Medical College, Beijing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cen</LastName><ForeName>Shan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences &amp;Peking Union Medical College, Beijing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Zhendong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>MOH Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, and Center for AIDS Research, Chinese Academy of Medical Sciences &amp;Peking Union Medical College, Beijing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jianwei</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>MOH Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, and Center for AIDS Research, Chinese Academy of Medical Sciences &amp;Peking Union Medical College, Beijing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>MOH Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, and Center for AIDS Research, Chinese Academy of Medical Sciences &amp;Peking Union Medical College, Beijing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>MOH Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, and Center for AIDS Research, Chinese Academy of Medical Sciences &amp;Peking Union Medical College, Beijing, P. R. China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lady Davis Institute, Jewish General Hospital, Montreal, Qc, Canada H3T 1E2.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ai</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Beijing Hospital, Beijing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>MOH Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, and Center for AIDS Research, Chinese Academy of Medical Sciences &amp;Peking Union Medical College, Beijing, P. R. China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CCI-132561</GrantID><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>7XU7A7DROE</RegistryNumber><NameOfSubstance UI="D000666">Amphotericin B</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000666" MajorTopicYN="N">Amphotericin B</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053586" MajorTopicYN="N">Virus Internalization</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>9</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27608771</ArticleId><ArticleId IdType="pmc">PMC5016833</ArticleId><ArticleId IdType="doi">10.1038/srep33150</ArticleId><ArticleId IdType="pii">srep33150</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hagiwara A., Tagaya I. &amp; Yoneyama T. Epidemic of hand, foot and mouth disease associated with enterovirus 71 infection. Intervirology 9, 60&#x2013;63 (1978).</Citation><ArticleIdList><ArticleId IdType="pubmed">202573</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M. et al.. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 341, 929&#x2013;935, 10.1056/NEJM199909233411301 (1999).</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199909233411301</ArticleId><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Tagaya I., Takayama R. &amp; Hagiwara A. A large-scale epidemic of hand, foot and mouth disease associated with enterovirus 71 infection in Japan in 1978. Jpn J Med Sci Biol 34, 191&#x2013;196 (1981).</Citation><ArticleIdList><ArticleId IdType="pubmed">6273621</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y. C. et al.. Clinicopathologic features and molecular analysis of enterovirus 71 infection: report of an autopsy case from the epidemic of hand, foot and mouth disease in China. Pathol Int 62, 565&#x2013;570, 10.1111/j.1440-1827.2012.02837.x (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1827.2012.02837.x</ArticleId><ArticleId IdType="pubmed">22827767</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L. Y. et al.. Neurodevelopment and cognition in children after enterovirus 71 infection. N Engl J Med 356, 1226&#x2013;1234, 10.1056/NEJMoa065954 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa065954</ArticleId><ArticleId IdType="pubmed">17377160</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J. et al.. EV71: an emerging infectious disease vaccine target in the Far East&#x2009;?&#x2009; Vaccine 28, 3516&#x2013;3521, 10.1016/j.vaccine.2010.03.003 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.03.003</ArticleId><ArticleId IdType="pubmed">20304038</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt N. J., Lennette E. H. &amp; Ho H. H. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis 129, 304&#x2013;309, 10.1093/infdis/129.3.304 (1974).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/129.3.304</ArticleId><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T. et al.. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 10, 778&#x2013;790, 10.1016/S1473-3099(10)70194-8 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S. M. &amp; Liu C. C. Enterovirus 71: epidemiology, pathogenesis and management. Expert Rev Anti Infect Ther 7, 735&#x2013;742, 10.1586/eri.09.45 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/eri.09.45</ArticleId><ArticleId IdType="pubmed">19681701</ArticleId></ArticleIdList></Reference><Reference><Citation>AbuBakar S. et al.. Identification of enterovirus 71 isolates from an outbreak of hand, foot and mouth disease (HFMD) with fatal cases of encephalomyelitis in Malaysia. Virus Res 61, 1&#x2013;9, 10.1016/S0168-1702(99)00019-2 (1999).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0168-1702(99)00019-2</ArticleId><ArticleId IdType="pubmed">10426204</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosoya M. et al.. Genetic diversity of enterovirus 71 associated with hand, foot and mouth disease epidemics in Japan from 1983 to 2003. Pediatr Infect Dis J 25, 691&#x2013;694, 10.1097/01.inf.0000227959.89339.c3 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.inf.0000227959.89339.c3</ArticleId><ArticleId IdType="pubmed">16874167</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding N. Z. et al.. Appearance of mosaic enterovirus 71 in the 2008 outbreak of China. Virus Res 145, 157&#x2013;161, 10.1016/j.virusres.2009.06.006 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2009.06.006</ArticleId><ArticleId IdType="pubmed">19540282</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y. et al.. Enterovirus 71 binding to PSGL-1 on leukocytes: VP1-145 acts as a molecular switch to control receptor interaction. PLoS Pathog 9, e1003511, 10.1371/journal.ppat.1003511 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003511</ArticleId><ArticleId IdType="pmc">PMC3723564</ArticleId><ArticleId IdType="pubmed">23935488</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan C. W., Poh C. L., Sam I. C. &amp; Chan Y. F. Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor. J Virol 87, 611&#x2013;620, 10.1128/JVI.02226-12 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02226-12</ArticleId><ArticleId IdType="pmc">PMC3536405</ArticleId><ArticleId IdType="pubmed">23097443</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S. et al.. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med 15, 798&#x2013;801, 10.1038/nm.1992 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1992</ArticleId><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y. &amp; Rossmann M. G. The cellular receptor for enterovirus 71. Protein Cell 5, 655&#x2013;657, 10.1007/s13238-014-0092-6 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-014-0092-6</ArticleId><ArticleId IdType="pmc">PMC4145082</ArticleId><ArticleId IdType="pubmed">25103897</ArticleId></ArticleIdList></Reference><Reference><Citation>Du N. et al.. Cell surface vimentin is an attachment receptor for enterovirus 71. J Virol 88, 5816&#x2013;5833, 10.1128/JVI.03826-13 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03826-13</ArticleId><ArticleId IdType="pmc">PMC4019121</ArticleId><ArticleId IdType="pubmed">24623428</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnard D. L. et al.. In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity. Antimicrob Agents Chemother 48, 1766&#x2013;1772, 10.1128/AAC.48.5.1766-1772.2004 (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.48.5.1766-1772.2004</ArticleId><ArticleId IdType="pmc">PMC400527</ArticleId><ArticleId IdType="pubmed">15105133</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih S. R. et al.. Mutation in enterovirus 71 capsid protein VP1 confers resistance to the inhibitory effects of pyridyl imidazolidinone. Antimicrob Agents Chemother 48, 3523&#x2013;3529, 10.1128/AAC.48.9.3523-3529.2004 (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.48.9.3523-3529.2004</ArticleId><ArticleId IdType="pmc">PMC514779</ArticleId><ArticleId IdType="pubmed">15328120</ArticleId></ArticleIdList></Reference><Reference><Citation>De Colibus L. et al.. More-powerful virus inhibitors from structure-based analysis of HEV71 capsid-binding molecules. Nat Struct Mol Biol 21, 282&#x2013;288, 10.1038/nsmb.2769 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2769</ArticleId><ArticleId IdType="pmc">PMC4530014</ArticleId><ArticleId IdType="pubmed">24509833</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews D. A. et al.. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc Natl Acad Sci USA 96, 11000&#x2013;11007, 10.1073/pnas.96.20.11000 (1999).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.96.20.11000</ArticleId><ArticleId IdType="pmc">PMC34232</ArticleId><ArticleId IdType="pubmed">10500114</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu G. et al.. Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. J Virol 85, 10319&#x2013;10331, 10.1128/JVI.00787-11 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00787-11</ArticleId><ArticleId IdType="pmc">PMC3196414</ArticleId><ArticleId IdType="pubmed">21795339</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragovich P. S. et al.. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements. J Med Chem 42, 1213&#x2013;1224, 10.1021/jm9805384 (1999).</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm9805384</ArticleId><ArticleId IdType="pubmed">10197965</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X. et al.. Rupintrivir is a promising candidate for treating severe cases of enterovirus-71 infection: evaluation of antiviral efficacy in a murine infection model. Antiviral Res 97, 264&#x2013;269, 10.1016/j.antiviral.2012.12.029 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2012.12.029</ArticleId><ArticleId IdType="pubmed">23295352</ArticleId></ArticleIdList></Reference><Reference><Citation>Pourianfar H. R., Poh C. L., Fecondo J. &amp; Grollo L. In vitro evaluation of the antiviral activity of heparan sulfate mimetic compounds against Enterovirus 71. Virus Res 169, 22&#x2013;29, 10.1016/j.virusres.2012.06.025 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2012.06.025</ArticleId><ArticleId IdType="pubmed">22771616</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T. C. et al.. Novel antiviral agent DTriP-22 targets RNA-dependent RNA polymerase of enterovirus 71. Antimicrob Agents Chemother 53, 2740&#x2013;2747, 10.1128/AAC.00101-09 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00101-09</ArticleId><ArticleId IdType="pmc">PMC2704669</ArticleId><ArticleId IdType="pubmed">19414569</ArticleId></ArticleIdList></Reference><Reference><Citation>Urbinati C., Chiodelli P. &amp; Rusnati M. Polyanionic drugs and viral oncogenesis: a novel approach to control infection, tumor-associated inflammation and angiogenesis. Molecules 13, 2758&#x2013;2785, 10.3390/molecules13112758 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules13112758</ArticleId><ArticleId IdType="pmc">PMC6245429</ArticleId><ArticleId IdType="pubmed">19002078</ArticleId></ArticleIdList></Reference><Reference><Citation>Goris N. et al.. 2&#x2032;-C-methylcytidine as a potent and selective inhibitor of the replication of foot-and-mouth disease virus. Antiviral Res 73, 161&#x2013;168, 10.1016/j.antiviral.2006.09.007 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2006.09.007</ArticleId><ArticleId IdType="pubmed">17055073</ArticleId></ArticleIdList></Reference><Reference><Citation>Graci J. D. et al.. Lethal mutagenesis of picornaviruses with N-6-modified purine nucleoside analogues. Antimicrob Agents Chemother 52, 971&#x2013;979, 10.1128/AAC.01056-07 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01056-07</ArticleId><ArticleId IdType="pmc">PMC2258490</ArticleId><ArticleId IdType="pubmed">18180344</ArticleId></ArticleIdList></Reference><Reference><Citation>Khong W. X. et al.. A non-mouse-adapted enterovirus 71 (EV71) strain exhibits neurotropism, causing neurological manifestations in a novel mouse model of EV71 infection. J Virol 86, 2121&#x2013;2131, 10.1128/JVI.06103-11 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.06103-11</ArticleId><ArticleId IdType="pmc">PMC3302383</ArticleId><ArticleId IdType="pubmed">22130542</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng C. L. et al.. Inhibition of enterovirus 71 by adenosine analog NITD008. J Virol 88, 11915&#x2013;11923, 10.1128/JVI.01207-14 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01207-14</ArticleId><ArticleId IdType="pmc">PMC4178731</ArticleId><ArticleId IdType="pubmed">25100827</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellmann R., Cleary J. D. &amp; Sterba J. Clinical roundtable monograph: safety and efficacy of lipid-based amphotericin B. Clin Adv Hematol Oncol 7, 1&#x2013;8 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19537331</ArticleId></ArticleIdList></Reference><Reference><Citation>Waheed A. A. et al.. Inhibition of human immunodeficiency virus type 1 assembly and release by the cholesterol-binding compound amphotericin B methyl ester: evidence for Vpu dependence. J Virol 82, 9776&#x2013;9781, 10.1128/JVI.00917-08 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00917-08</ArticleId><ArticleId IdType="pmc">PMC2546975</ArticleId><ArticleId IdType="pubmed">18653459</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen J. E. et al.. Derivatives of amphotericin inhibit infection with human immunodeficiency virus in vitro by different modes of action. Antiviral Res 14, 149&#x2013;159, 10.1016/0166-3542(90)90031-2 (1990).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0166-3542(90)90031-2</ArticleId><ArticleId IdType="pubmed">2080870</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan G. W., Humphreys S. &amp; Zee Y. C. Effect of amphotericin B methyl ester on vesicular stomatitis virus morphology. Antimicrob Agents Chemother 13, 340&#x2013;341, 10.1128/AAC.13.2.340 (1978).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.13.2.340</ArticleId><ArticleId IdType="pmc">PMC352237</ArticleId><ArticleId IdType="pubmed">206202</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessler H. A., Dixon J., Howard C. R., Tsiquaye K. &amp; Zuckerman A. J. Effects of amphotericin B on hepatitis B virus. Antimicrob Agents Chemother 20, 826&#x2013;833, 10.1128/AAC.20.6.826 (1981).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.20.6.826</ArticleId><ArticleId IdType="pmc">PMC181806</ArticleId><ArticleId IdType="pubmed">7325646</ArticleId></ArticleIdList></Reference><Reference><Citation>Pleskoff O., Seman M. &amp; Alizon M. Amphotericin B derivative blocks human immunodeficiency virus type 1 entry after CD4 binding: effect on virus-cell fusion but not on cell-cell fusion. J Virol 69, 570&#x2013;574 (1995).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC188612</ArticleId><ArticleId IdType="pubmed">7983757</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens N. M., Engle C. G., Fisher P. B., Mechlinski W. &amp; Schaffner C. P. In vitro antiherpetic activity of water-soluble amphotericin B methyl ester. Arch Virol 48, 391&#x2013;394 (1975).</Citation><ArticleIdList><ArticleId IdType="pubmed">173265</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan G. W. &amp; Seet E. C. Antiviral effects of amphotericin B methyl ester. Antimicrob Agents Chemother 13, 199&#x2013;204, 10.1128/AAC.13.2.199 (1978).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.13.2.199</ArticleId><ArticleId IdType="pmc">PMC352214</ArticleId><ArticleId IdType="pubmed">206201</ArticleId></ArticleIdList></Reference><Reference><Citation>Seok H. et al.. Disseminated Talaromyces marneffei and Mycobacterium intracellulare coinfection in an HIV-infected patient. Int J Infect Dis, 10.1016/j.ijid.2015.07.020 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2015.07.020</ArticleId><ArticleId IdType="pubmed">26232630</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahajan R. et al.. Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India. Clin Infect Dis, 10.1093/cid/civ530 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/civ530</ArticleId><ArticleId IdType="pmc">PMC4583582</ArticleId><ArticleId IdType="pubmed">26129756</ArticleId></ArticleIdList></Reference><Reference><Citation>Roethl E. et al.. Antimycotic-antibiotic amphotericin B promotes influenza virus replication in cell culture. J Virol 85, 11139&#x2013;11145, 10.1128/JVI.00169-11 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00169-11</ArticleId><ArticleId IdType="pmc">PMC3194987</ArticleId><ArticleId IdType="pubmed">21849438</ArticleId></ArticleIdList></Reference><Reference><Citation>Waheed A. A. et al.. Inhibition of HIV-1 replication by amphotericin B methyl ester: selection for resistant variants. J Biol Chem 281, 28699&#x2013;28711, 10.1074/jbc.M603609200 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M603609200</ArticleId><ArticleId IdType="pubmed">16882663</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen J. et al.. The major cellular sterol regulatory pathway is required for Andes virus infection. PLoS Pathog 10, e1003911, 10.1371/journal.ppat.1003911 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003911</ArticleId><ArticleId IdType="pmc">PMC3916400</ArticleId><ArticleId IdType="pubmed">24516383</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordey S. et al.. Identification of site-specific adaptations conferring increased neural cell tropism during human enterovirus 71 infection. PLoS Pathog 8, e1002826, 10.1371/journal.ppat.1002826 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002826</ArticleId><ArticleId IdType="pmc">PMC3406088</ArticleId><ArticleId IdType="pubmed">22910880</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan F. Enterovirus D68: acute respiratory illness and the 2014 outbreak. Emerg Med Clin North Am 33, e19&#x2013;e32 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26065305</ArticleId></ArticleIdList></Reference><Reference><Citation>Waghmare A. et al.. Clinical disease due to enterovirus D68 in adult hematologic malignancy patients and hematopoietic cell transplant recipients. Blood 125, 1724&#x2013;1729, 10.1182/blood-2014-12-616516 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2014-12-616516</ArticleId><ArticleId IdType="pmc">PMC4357580</ArticleId><ArticleId IdType="pubmed">25593338</ArticleId></ArticleIdList></Reference><Reference><Citation>da Silva E. E., Winkler M. T. &amp; Pallansch M. A. Role of enterovirus 71 in acute flaccid paralysis after the eradication of poliovirus in Brazil. Emerg Infect Dis 2, 231&#x2013;233, 10.3201/eid0203.960312 (1996).</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid0203.960312</ArticleId><ArticleId IdType="pmc">PMC2626804</ArticleId><ArticleId IdType="pubmed">8903236</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert G. L. et al.. Outbreak of enterovirus 71 infection in Victoria, Australia, with a high incidence of neurologic involvement. Pediatr Infect Dis J 7, 484&#x2013;488 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">2841639</ArticleId></ArticleIdList></Reference><Reference><Citation>Khetsuriani N., Lamonte-Fowlkes A., Oberst S. &amp; Pallansch M. A. Enterovirus surveillance&#x2013;United States, 1970&#x2013;2005. MMWR Surveill Summ 55, 1&#x2013;20 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16971890</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu K. X., Ng M. M. &amp; Chu J. J. Developments towards antiviral therapies against enterovirus 71. Drug Discov Today 15, 1041&#x2013;1051, 10.1016/j.drudis.2010.10.008 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2010.10.008</ArticleId><ArticleId IdType="pmc">PMC7108380</ArticleId><ArticleId IdType="pubmed">20974282</ArticleId></ArticleIdList></Reference><Reference><Citation>McKinsey D. S. et al.. Long-term amphotericin B therapy for disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 111, 655&#x2013;659, 10.7326/0003-4819-111-8-655 (1989).</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-111-8-655</ArticleId><ArticleId IdType="pubmed">2802421</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontani D. R. et al.. Inhibition of HIV replication by liposomal encapsulated amphotericin B. Antiviral Res 11, 119&#x2013;125, 10.1016/0166-3542(89)90023-5 (1989).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0166-3542(89)90023-5</ArticleId><ArticleId IdType="pubmed">2472114</ArticleId></ArticleIdList></Reference><Reference><Citation>Clayette P. et al.. Effects of MS-8209, an amphotericin B derivative, on tumor necrosis factor alpha synthesis and human immunodeficiency virus replication in macrophages. Antimicrob Agents Chemother 44, 405&#x2013;407, 10.1128/AAC.44.2.405-407.2000 (2000).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.44.2.405-407.2000</ArticleId><ArticleId IdType="pmc">PMC89691</ArticleId><ArticleId IdType="pubmed">10639370</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson T. M. et al.. Amphotericin forms an extramembranous and fungicidal sterol sponge. Nat Chem Biol 10, 400&#x2013;406, 10.1038/nchembio.1496 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.1496</ArticleId><ArticleId IdType="pmc">PMC3992202</ArticleId><ArticleId IdType="pubmed">24681535</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis S. A. et al.. Nontoxic antimicrobials that evade drug resistance. Nat Chem Biol 11, 481&#x2013;487, 10.1038/nchembio.1821 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.1821</ArticleId><ArticleId IdType="pmc">PMC4472574</ArticleId><ArticleId IdType="pubmed">26030729</ArticleId></ArticleIdList></Reference><Reference><Citation>Ran Z. et al.. In vitro and in vivo replication of influenza A H1N1 WSN33 viruses with different M1 proteins. J Gen Virol 94, 884&#x2013;895, 10.1099/vir.0.046219-0 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.046219-0</ArticleId><ArticleId IdType="pmc">PMC3709687</ArticleId><ArticleId IdType="pubmed">23255622</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang Z. et al.. Enterovirus 68 3C protease cleaves TRIF to attenuate antiviral responses mediated by Toll-like receptor 3. J Virol 88, 6650&#x2013;6659, 10.1128/JVI.03138-13 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03138-13</ArticleId><ArticleId IdType="pmc">PMC4054379</ArticleId><ArticleId IdType="pubmed">24672048</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>